| Literature DB >> 24255598 |
Predrag Erceg1, Nebojsa Despotovic, Dragoslav P Milosevic, Ivan Soldatovic, Sanja Zdravkovic, Snezana Tomic, Ivana Markovic, Gordana Mihajlovic, Milan D Brajovic, Ognjen Bojovic, Bojana Potic, Mladen Davidovic.
Abstract
BACKGROUND: Chronic heart failure is a very common condition in the elderly, characterized not only by high mortality rates, but also by a strong impact on health-related quality of life (HRQOL). Previous studies of HRQOL in elderly heart failure subjects have included mostly outpatients, and little is known about determinants of HRQOL in hospitalized elderly population, especially in Serbia. In this study, we tried to identify factors that influence HRQOL in elderly patients hospitalized with chronic heart failure in Serbia.Entities:
Keywords: depression; elderly; heart disease; self-perception of health
Mesh:
Year: 2013 PMID: 24255598 PMCID: PMC3832382 DOI: 10.2147/CIA.S53305
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Baseline patient characteristics (n=136)
| Characteristic | Value |
|---|---|
| Age (years) | 77.8±5.9 |
| Male sex | 72 (52.9) |
| Marital status | |
| Married | 47 (34.6) |
| Single, divorced, widowed | 89 (65.4) |
| Education | |
| >12 years | 27 (19.9) |
| ≤12 years | 109 (80.1) |
| Number of household members | 2.4±1.4 |
| Household income (monthly, US dollars) | 447.2±297.7 |
| Duration of CHF (months) | 61.9±71.1 |
| Previous | |
| Myocardial infarction | 44 (32.4) |
| Angina | 80 (58.8) |
| Hypertension | 101 (74.3) |
| Diabetes mellitus | 42 (30.9) |
| Three or more comorbidities | 90 (66.2) |
| Current medications | |
| Diuretics | 128 (94.1) |
| Aldosterone antagonists | 67 (49.3) |
| ACEIs | 104 (76.5) |
| ARBs | 3 (2.2) |
| Beta-blockers | 69 (50.7) |
| Digoxin | 41 (30.1) |
| Anticoagulants | 51 (37.5) |
| Number of drugs | 6.9±2.3 |
| NYHA class | |
| I | 2 (1.5) |
| II | 36 (26.5) |
| III | 63 (46.3) |
| IV | 35 (25.7) |
| LVEF (%) | 40.9±11.0 |
| Depressive symptoms | 76 (55.9) |
| Cognitive impairment | 71 (52.2) |
| Length of hospital stay (days) | 18.0±9.5 |
| MLHFQ score | |
| Total | 50.4±19.3 |
| Physical | 25.3±9.4 |
| Emotional | 10.6±6.5 |
Notes: Data are presented as the mean ± standard deviation or number (%).
Abbreviations: CHF, chronic heart failure; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure questionnaire.
Demographic factors associated with health-related quality of lifea
| Total | Physical | Emotional | ||||
|---|---|---|---|---|---|---|
| Age | −0.070 | 0.420 | −0.043 | 0.620 | 0.024 | 0.777 |
| Gender | ||||||
| Male | 48.6±19.7 | 0.227 | 24.0±9.8 | 0.075 | 10.1±6.0 | 0.264 |
| Female | 52.3±18.7 | 26.9±8.8 | 11.3±7.0 | |||
| Marital status | ||||||
| Married | 50.9±20.4 | 0.810 | 25.1±9.6 | 0.810 | 10.4±6.4 | 0.824 |
| Unmarried | 50.1±18.8 | 25.5±9.4 | 10.8±6.6 | |||
| Education | −0.135 | 0.118 | −0.179 | 0.038 | −0.142 | 0.102 |
| Number of household members | 0.121 | 0.161 | 0.081 | 0.347 | 0.181 | 0.035 |
| Household income | −0.252 | 0.013 | −0.254 | 0.012 | −0.057 | 0.576 |
Notes:
Univariate analysis. HRQOL was assessed using the MLHFQ; higher scores represent more impaired HRQOL. Data are presented as the mean ± standard deviation, Pearson’s product-moment correlation coefficient, or Spearman’s rank correlation coefficient.
Abbreviations: MLHFQ, Minnesota Living with Heart Failure questionnaire; HRQOL, health-related quality of life.
Clinical factors associated with health-related quality of lifea
| Total | Physical | Emotional | ||||
|---|---|---|---|---|---|---|
| Duration of CHF | 0.224 | 0.010 | 0.223 | 0.011 | 0.151 | 0.085 |
| Previous MI | ||||||
| Yes | 52.0±19.0 | 0.373 | 25.5±10.3 | 0.684 | 11.2±6.2 | 0.418 |
| No | 49.6±19.4 | 25.3±9.0 | 10.4±6.6 | |||
| Previous AP | ||||||
| Yes | 51.6±19.0 | 0.325 | 25.8±9.9 | 0.344 | 10.8±6.6 | 0.796 |
| No | 48.6±19.6 | 24.7±8.7 | 10.5±6.4 | |||
| Hypertension | ||||||
| Yes | 49.1±19.9 | 0.130 | 24.8±9.4 | 0.255 | 10.1±6.5 | 0.084 |
| No | 54.0±17.1 | 26.9±9.5 | 12.2±6.4 | |||
| Diabetes mellitus | ||||||
| Yes | 49.8±17.9 | 0.904 | 24.0±8.9 | 0.180 | 11.3±6.7 | 0.365 |
| No | 50.6±19.9 | 25.9±9.6 | 10.3±6.4 | |||
| Number of comorbidities | −0.053 | 0.538 | −0.045 | 0.604 | −0.039 | 0.649 |
| NYHA class | ||||||
| I or II | 39.3±18.2 | <0.001 | 19.3±9.8 | <0.001 | 8.5±5.5 | 0.023 |
| III or IV | 54.7±18.0 | 27.7±8.2 | 11.5±6.6 | |||
| LVEF (%) | ||||||
| ≥40 | 49.3±18.7 | 0.661 | 25.1±9.1 | 0.699 | 10.7±6.4 | 0.568 |
| <40 | 51.5±19.9 | 25.5±9.9 | 10.4±6.6 | |||
| Depressive symptoms | ||||||
| Yes | 57.9±17.6 | <0.001 | 28.5±8.9 | <0.001 | 13.1±6.4 | <0.001 |
| No | 40.9±17.1 | 21.4±8.6 | 7.5±5.0 | |||
| Cognitive impairment | ||||||
| Yes | 53.8±20.7 | 0.030 | 26.6±9.8 | 0.062 | 12.1±7.2 | 0.022 |
| No | 46.7±17.0 | 24.0±8.9 | 9.1±5.2 | |||
| Length of hospital stay | 0.198 | 0.021 | 0.162 | 0.060 | 0.199 | 0.020 |
Notes:
Univariate analysis. HRQOL was assessed using the Minnesota Living with Heart Failure questionnaire; higher scores represent more impaired HRQOL. Data are presented as the mean ± standard deviation, Pearson’s product-moment correlation coefficient, or Spearman’s rank correlation coefficient.
Abbreviations: MLHFQ, Minnesota Living with Heart Failure questionnaire; CHF, chronic heart failure; MI, myocardial infarction; AP, angina pectoris; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HRQOL, health-related quality of life.
Current medications associated with health-related quality of lifea
| Total | Physical | Emotional | ||||
|---|---|---|---|---|---|---|
| Diuretics | ||||||
| Yes | 51.1±19.4 | 0.060 | 25.6±9.4 | 0.109 | 10.8±6.6 | 0.496 |
| No | 38.4±13.9 | 20.6±8.9 | 8.9±4.1 | |||
| Aldosterone antagonists | ||||||
| Yes | 53.7±20.2 | 0.046 | 26.9±9.3 | 0.048 | 11.4±7.0 | 0.231 |
| No | 47.2±17.9 | 23.8±9.3 | 9.9±6.0 | |||
| ACEIs | ||||||
| Yes | 50.8±20.2 | 0.731 | 25.0±9.5 | 0.443 | 11.1±6.7 | 0.230 |
| No | 49.0±16.2 | 26.4±9.3 | 9.2±5.6 | |||
| Beta-blockers | ||||||
| Yes | 49.6±21.4 | 0.555 | 24.4±10.0 | 0.272 | 10.9±7.0 | 0.709 |
| No | 51.2±17.0 | 26.3±8.7 | 10.4±5.9 | |||
| Digoxin | ||||||
| Yes | 54.5±17.8 | 0.049 | 27.2±9.0 | 0.128 | 12.1±6.8 | 0.115 |
| No | 48.6±19.7 | 24.6±9.5 | 10.0±6.3 | |||
| Anticoagulants | ||||||
| Yes | 49.6±19.0 | 0.681 | 24.3±8.8 | 0.219 | 10.5±6.6 | 0.751 |
| No | 50.8±19.5 | 26.0±9.8 | 10.7±6.4 | |||
| Number of drugs | 0.170 | 0.047 | 0.146 | 0.090 | 0.119 | 0.168 |
Notes:
Univariate analysis. HRQOL was assessed using the Minnesota Living with Heart Failure questionnaire; higher scores represent more impaired HRQOL. Data are presented as the mean ± standard deviation or Spearman’s rank correlation coefficient.
Abbreviations: MLHFQ, Minnesota Living with Heart Failure questionnaire; ACEIs, angiotensin-converting enzyme inhibitors; HRQOL, health-related quality of life.
Independent predictors of health-related quality of lifea
| Depressive symptoms | 0.407 | <0.001 |
| NYHA class | 0.229 | 0.021 |
| Duration of CHF | 0.179 | 0.049 |
| Digoxin | 0.139 | 0.125 |
| Income | −0.206 | 0.029 |
| Length of hospital stay | 0.105 | 0.240 |
| Diuretics | −0.039 | 0.682 |
| Cognitive impairment | 0.005 | 0.959 |
| Aldosterone antagonists | −0.023 | 0.811 |
| Number of drugs | 0.027 | 0.784 |
Notes:
Multiple linear regression analysis. R2=0.402; R2 (adjusted) =0.330. HRQOL was assessed using the Minnesota Living with Heart Failure questionnaire.
Abbreviations: HRQOL, health-related quality of life; NYHA, New York Heart Association; Sβ, standard partial regression coefficient; CHF, chronic heart failure; R2, coefficient of determination.